8-K: Cibus Reports First Quarter 2025 Financial Results and Provides Business Update

Cibus Inc. announced its Q1 2025 financial results, highlighting progress in rice and canola trait development, regulatory advancements, and ongoing efforts to secure additional funding.

Summary

• Cibus Inc. released its financial results for the first quarter of 2025 and provided a business update.
• The company's cash and cash equivalents totaled $23.6 million as of March 31, 2025.
• Cibus anticipates that its current cash reserves will sustain planned operations into the third quarter of 2025, considering cost-saving measures.
• The company is actively exploring strategic alternatives to enhance shareholder value.
• Research and development expenses for Q1 2025 were $11.8 million, slightly lower than the $12.0 million reported in the same period last year.
• Selling, general, and administrative expenses increased to $9.9 million, up from $7.0 million in the prior year, primarily due to a $3.0 million estimated litigation liability.
• A goodwill impairment charge of $21.0 million was recorded in Q1 2025 due to a decline in the company's stock price.
• The net loss for the quarter was $49.4 million, compared to a $27.0 million loss in the same period of the previous year.
• The net loss per share of Class A common stock was $1.34, compared to $1.12 in the year-ago period.
• Cibus is making progress in its rice business, with its first stacked gene-edited herbicide tolerance traits.
• The company is on track for a targeted commercial launch of HT1 and HT3 traits in 2027, with customer germplasm integration underway.
• Ecuador has provided a positive regulatory decision for Cibus' rice traits HT1 and HT3.
• The company's disease resistance program is advancing, with positive Sclerotinia data for multiple modes of action in canola.
• The USDA-APHIS has designated canola disease resistance traits as not regulated.
• EU member states have endorsed the EU Council's negotiating mandate on the regulation of plants obtained by New Genomic Techniques (NGTs).

Sentiment

Score: 4

Explanation: The company is making progress in its technology and has achieved some regulatory milestones, but the financial results are poor and the company needs to raise capital soon.

Positives

• Cibus is making progress in its rice business with stacked gene-edited herbicide tolerance traits.
• Ecuador has provided a positive regulatory decision for Cibus' rice traits HT1 and HT3.
• The USDA-APHIS has designated canola disease resistance traits as not regulated.
• EU member states have endorsed the EU Council's negotiating mandate on the regulation of plants obtained by New Genomic Techniques (NGTs).
• The company is advancing its disease resistance program with positive Sclerotinia data for multiple modes of action in canola.
• Cibus successfully edited a Soybean cell for its HT2 trait, achieving sufficiently high editing rates that enabled expanded development of its Soybean platform.
• The California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting in California.

Negatives

• Cibus reported a net loss of $49.4 million for Q1 2025, compared to a $27.0 million loss in the same period last year.
• The company recorded a $21.0 million goodwill impairment charge due to a decline in its stock price.
• Selling, general, and administrative expenses increased to $9.9 million, primarily due to a $3.0 million estimated litigation liability.
• The company's cash reserves are expected to last only into the third quarter of 2025 without additional funding.

Risks

• Cibus needs additional near-term funding to finance its activities and faces challenges in obtaining additional capital on acceptable terms.
• There are risks associated with changes in expected or existing competition.
• Challenges to Cibus' intellectual property protection and unexpected costs associated with defending intellectual property rights could arise.
• Increased or unanticipated time and resources may be required for Cibus' platform or trait product development efforts.
• Cibus relies on third parties in connection with its development activities.
• There are challenges associated with Cibus' ability to effectively license its productivity traits and sustainable ingredient products.
• Farmers may not recognize the value in germplasm containing Cibus' traits.
• Delays and uncertainties regarding regulatory developments in the European Union could occur.
• Commodity prices and other market risks facing the agricultural sector could impact Cibus.
• Technological developments could render Cibus' technologies obsolete.
• Changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates, could pose risks.
• Dislocations in the capital markets and challenges in accessing liquidity could impact Cibus' ability to execute on its business plan.

Future Outlook

Cibus expects to report ordinary course development progress and achievements in connection with its quarterly reporting process and is targeting commercial launch of HT1 and HT3 traits in 2027. Cibus expects that existing cash and cash equivalents is sufficient to fund planned operating expenses and capital expenditure requirements into the third quarter of 2025.

Management Comments

• Peter Beetham stated that the company's RTDS technology platform is generating significant commercial interest.
• Peter Beetham noted the USDA-APHIS designation of canola disease resistance traits as not regulated and the California Rice Commission's approval of gene-edited rice planting as important acceptance of the company's technology.
• Peter Beetham highlighted the company's ability to deliver edited traits in under 12 months, creating a predictable path to commercialization.

Industry Context

Cibus operates in the agricultural biotechnology industry, focusing on gene editing to develop plant traits. The company's progress in rice and canola trait development, along with regulatory approvals, positions it to compete with other companies in the industry, such as Bayer Crop Science, Corteva Agriscience, and Syngenta. The increasing acceptance of gene-edited crops by regulatory bodies and the market is a positive trend for Cibus.

Comparison to Industry Standards

• Cibus' RTDS technology, which aims to deliver edited traits in under 12 months, is faster than traditional breeding methods, which can take several years.
• The $23.6 million in cash and cash equivalents is low compared to larger agricultural companies like Bayer or Corteva, which have billions in cash reserves.
• The net loss of $49.4 million is significant, but not uncommon for early-stage biotech companies investing heavily in R&D.
• The positive regulatory decisions in Ecuador and the US are important milestones, as regulatory hurdles are a major challenge for gene-edited crops.
• The collaboration with Biographica to leverage AI for disease resistance is in line with industry trends of using advanced technologies to improve crop development.

Related Party Transactions

• Royalty liability interest expense related parties was $8.4 million for the quarter ended March 31, 2025.

Stakeholder Impact

• Shareholders are impacted by the net loss and the need for additional funding.
• Employees are impacted by the cost-saving initiatives.
• Customers (seed companies) benefit from the development of new traits.
• Farmers benefit from the potential for improved crop yields and disease resistance.

Next Steps

• Expand existing and develop new commercial relationships with rice seed companies across North and South America during the course of 2025.
• Prepare delivery of initial traits to a California customer in mid-2025.
• Prepare delivery of initial traits to a Latin American customer by end of 2025.
• Field trials for third and fourth modes of action in Canola planned for 2025.
• Continue progress on partner-funded project to develop sustainable low carbon ingredients or materials for the CPG industry during the course of 2025.

Key Dates

Keywords

Cibus, gene editing, agricultural biotechnology, plant traits, rice, canola, Sclerotinia, herbicide tolerance, RTDS, financial results, regulatory approval, soybean, sustainable ingredients